Rachel Sha is the Vice President of Digital Business Development & Licensing at Sanofi. She leads a team of Business Development professionals driving transactions from identifying new opportunities to closing deals across therapeutic areas in digital health with the goal of discovering, developing and bringing to market solutions that improve outcomes and experience at reduced costs. Some partnering deals Rachel has led include Science 37, which enables decentralized clinical studies, and Evidation Health, a leader in behavior analytics. She co-led the transaction with Verily Life Sciences in diabetes and was the alliance manager for the collaboration with Verily Life Sciences , leading the joint venture formation, called Onduo. Additionally, Rachel serves on the Life Sciences Council of Springboard Enterprises, which is focused on supporting women-led companies grow and expand, is a judge for Mass Challenge and MIT Lemelson Student Prize. She joined Genzyme in 2005 and has held roles with increasing responsibility in Business Development, Corporate Development and Global Marketing & Strategy for Genzyme and Sanofi. Prior to Sanofi, Rachel was a manager at Accenture, where she focused on a broad range of business issues from strategy to process to technology implementation across a diverse set of industries with focus in electronics & high tech in particular. Rachel holds a Bachelor of Science degree in Chemistry from Massachusetts Institute of Technology and an MBA from Harvard Business School.